1. Home
  2. PCSA vs DUO Comparison

PCSA vs DUO Comparison

Compare PCSA & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$3.56

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.60

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
DUO
Founded
2011
2011
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
7.5M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PCSA
DUO
Price
$3.56
$1.60
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
321.0K
66.1K
Earning Date
11-06-2025
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$56,189,313.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
48.30
52 Week Low
$2.74
$1.24
52 Week High
$22.80
$11.46

Technical Indicators

Market Signals
Indicator
PCSA
DUO
Relative Strength Index (RSI) 59.91 44.25
Support Level $3.07 $1.54
Resistance Level $3.80 $1.68
Average True Range (ATR) 0.31 0.09
MACD -0.08 0.01
Stochastic Oscillator 67.27 40.00

Price Performance

Historical Comparison
PCSA
DUO

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

Share on Social Networks: